Menssana Research specializes in innovative breath analysis technologies, particularly through their BreathX system. This system is designed to detect various diseases, including cancers and infections, by analyzing volatile organic compounds (VOCs) present in exhaled breath. The BreathX technology leverages advanced sensor systems and analytical methods to provide non-invasive diagnostics, offering a promising alternative to traditional testing methods.

The company focuses on the scientific principles behind breath analysis, emphasizing the potential of VOCs as biomarkers for different health conditions. By utilizing sophisticated algorithms and data analysis techniques, Menssana Research aims to enhance the accuracy and reliability of disease detection, ultimately contributing to improved patient outcomes. Their ongoing research and development efforts are geared towards expanding the applications of breath analysis in clinical settings, making it a valuable tool in modern medicine.

United States

Menssana Research is the leading developer of advanced new breath tests for detection of disease. 

We are now performing clinical studies with the BCA and with BreathLink (TM), mostly funded by the National Institutes of Health and BARDA, to evaluate breath testing in several diseases including lung cancer, breast cancer, heart transplant rejection, radiation exposure, and tuberculosis. The Food and Drug Administration has approved the Heartsbreath test for heart transplant rejection for clinical use.

For more information, please visit menssanaresearch.com.

Menssana Research

Company Details